Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.

NCT07752784 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: [18F]-APN-1607

Sponsor

JYAMS PET Research & Development Limited